Ā | Milan cohort | Naples cohort | All patients |
---|---|---|---|
Number of patients | 122 | 97 | 219 |
Male/female ratio | 8/114 | 9/88 | 17/202 |
Median age, years (range) | 52 (17ā82) | 55 (19ā79) | 54 (17ā82) |
Median disease duration, years (range) | 4 (0ā28) | 6 (0ā36) | 5 (0ā36) |
lcSSc/dcSSc | 60/62 | 72/25 | 132/87 |
Autoantibodies | |||
āACAs | 57 | 53 | 110 |
āAnti-Scl-70 | 58 | 22 | 80 |
āOthers | 7 | 22 | 29 |
ESSG index ā„3, n (%) | 57 (46.8) | 30 (30.9) | 87 (39.7) |
ESSG index ā„3.5, n (%) | 49 (40.2) | 20 (20.6) | 69 (31.5) |
Mean mRSS (range) | 5.9 (0ā22) | 3.4 (0ā23) | 4.6 (0ā23) |
Scleroderma, n (%) | 74 (60.7) | 17 (17.5) | 91 (41.5) |
Change in skin involvementa, n (%) | 35 (28.7) | 23 (23.7) | 58 (26.4) |
Ulcers, n (%) | 34 (27.9) | 11 (11.3) | 45 (20.5) |
Change in vascular featuresa,b, n (%) | 56 (46.7) | 19 (19.5) | 75 (34.2) |
Arthritis, n (%) | 30 (24.6) | 7 (7.2) | 37 (16.8) |
DLCO <80%, n (%) | 86 (71.3) | 85 (87.6) | 171 (78) |
Change in cardiopulmonary featuresa,c, n (%) | 25 (20.5) | 19 (19.5) | 44 (20) |
ESR >30Ā mm/h, n (%) | 33 (27) | 35 (36) | 68 (31.1) |
Low complement, n (%) | 15 (12.3) | 13 (13.4) | 28 (12.7) |